P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Tao, Huiren ^a,b   Okamoto, Mina ^a   Nishikawa, Masataka ^a   Yoshikawa, Hideki ^a   Myoui, Akira ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN C FOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; ACID PHOSPHATASE; CALCIUM; ISOENZYME; NFATC1 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG INHIBITION; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; ANIMAL; BLOOD; BONE DEVELOPMENT; CELL COUNT; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; OSTEOCLAST; PATHOLOGY;

ACID PHOSPHATASE; ANIMALS; BONE RESORPTION; CALCIUM; CELL COUNT; CELLS, CULTURED; HUMANS; HYPERCALCEMIA; ISOENZYMES; MALE; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID HORMONE-RELATED PROTEIN; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; PYRIDINES; RANK LIGAND;

EID: 80052015103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023199     Document Type: Article

References (37)

1. Wysolmerski JJ, Broadus AE, (1994) Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med 45: 189-200.
2. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
3. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206.
4. Mundy GR, Yoneda T, (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339: 398-400.
5. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, et al. (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36: 615-620.
6. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.
9. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
10. Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T, et al. (2011) The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 17: 462-468.
11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268.
12. Anandarajah AP, (2009) Role of RANKL in bone diseases. Trends Endocrinol Metab 20: 88-94.
13. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M, (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275: 31155-31161.
14. Li X, Udagawa N, Itoh K, Suda K, Murase Y, et al. (2002) p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143: 3105-3113.
15. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M, (1996) Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 314: 137-142.
16. Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, et al. (1997) FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 327: 169-174.
17. Takahashi S, Keto Y, Fujita T, Uchiyama T, Yamamoto A, (2001) FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther 296: 48-56.
18. Cau J, Favreau F, Zhang K, Febrer G, de la Motte GR, et al. (2009) FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury. J Vasc Surg 49: 728-740.
19. Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, et al. (2001) Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 29: 628-634.
20. Nishikori T, Irie K, Suganuma T, Ozaki M, Yoshioka T, (2002) Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation. Eur J Pharmacol 451: 327-333.
21. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, et al. (2002) Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant 17: 399-407.
22. Hou Z, Yanaga K, Kamohara Y, Eguchi S, Tsutsumi R, et al. (2003) A new suppressive agent against interleukin-1beta and tumor necrosis factor-alpha enhances liver regeneration after partial hepatectomy in rats. Hepatol Res 26: 40-46.
23. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, et al. (2003) Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48: 2670-2681.
24. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A, (2000) Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275: 4858-4864.
25. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, et al. (2006) Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 351: 99-105.
26. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR, (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125: 1142-1150.
27. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, et al. (1999) A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 14: 1478-1485.
28. Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M, (2000) Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 486: 23-28.
29. Brandstrom H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S, et al. (1998) Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 247: 338-341.
30. Horwood NJ, Elliott J, Martin TJ, Gillespie MT, (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139: 4743-4746.
31. Magno AL, Ward BK, Ratajczak T, (2011) The calcium-sensing receptor: a molecular perspective. Endocr Rev 32: 3-30.
32. Brown EM, MacLeod RJ, (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297.
33. Tfelt-Hansen J, MacLeod RJ, Chattopadhyay N, Yano S, Quinn S, et al. (2003) Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab 285: E329-337.
34. Morgan R, Fairfax B, Pandha HS, (2006) Calcium insensitivity of FA-6, a cell line derived from a pancreatic cancer associated with humoral hypercalcemia, is mediated by the significantly reduced expression of the Calcium Sensitive Receptor transduction component p38 MAPK. Mol Cancer 5: 51.
35. Startchik I, Morabito D, Lang U, Rossier MF, (2002) Control of calcium homeostasis by angiotensin II in adrenal glomerulosa cells through activation of p38 MAPK. J Biol Chem 277: 24265-24273.
36. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, et al. (2000) A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 11: 1534-1541.
37. Gardiner SM, Kemp PA, March JE, Bennett T, (1999) Influence of FR167653, an inhibitor of TNF-alpha and IL-1, on the cardiovascular responses to chronic infusion of lipopolysaccharide in conscious rats. J Cardiovasc Pharmacol 34: 64-69.